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Abstract 1 
Objectives: Evaluate a nadir-led protocol for transitioning porcine lente insulin suspension (PLIS)-treated 2 
diabetic cats onto human recombinant protamine zinc insulin (PZIR). 3 
Methods: Recently-diagnosed (<5 months) diabetic cats, treated with twice-daily (BID) PLIS for ≥6 weeks, 4 
were recruited. Fructosamine, 24-hour blood glucose curve (BGC), quality of life assessment (DIAQoL-pet 5 
score), and Diabetic Clinical Score (DCS) were assessed on enrolment (during PLIS treatment), and 2, 4 6 
and 12 weeks after transitioning to PZIR (starting dose 0.2-0.7U/kg BID). Short duration of insulin-action 7 
was defined as <9 hours. Linear mixed effects modelling assessed for change in fructosamine, mean blood 8 
glucose (MBG) during BGCs, DIAQoL-pet score, DCS, and BID insulin dose. McNemar’s tests compared the 9 
proportion of cats with hypoglycaemia at week 0 (PLIS-treated) and week 4 (PZIR-treated).  10 
Results: Twenty-two cats were recruited. Median PLIS dose at enrolment was 0.5U/kg (interquartile range 11 
(IQR) 0.3–0.7U/kg) BID, equalling median PZIR starting dose (0.5, IQR 0.3-0.7U/kg BID). Transitioning was 12 
followed by significant decreases in fructosamine (p=0.00007), insulin dose (p=0.02), DCS (p=8.1x10-8) and 13 
DIAQoL-pet score (p=0.003), indicating improved quality of life. MBG did not alter significantly (p=0.1). 14 
Five cats (22.7%) achieved diabetic remission. Hypoglycaemia was recorded in 30 of 190 12-hour BGCs 15 
(15.8%) and five cats experienced clinical hypoglycaemia. Proportion of cats with hypoglycaemia did not 16 
differ between PLIS (week 0) and PZIR (week 4) (p=1.0). Duration of action was analysed in 19 cats. Six 17 
cats (31.6%) showed short duration of action on PLIS, compared to 2 cats (10.5%) after 4 weeks on PZIR. 18 
All six cats with short PLIS duration showed duration of ≥9 hours on PZIR.  19 
Conclusions and Relevance: All cats transitioned successfully. Transitioning was associated with 20 
significantly improved clinical signs and quality of life, with some cats achieving remission. Transition to 21 
PZIR should be considered for cats with short duration of action on PLIS. 22 
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Introduction 23 
The major goals in managing feline diabetes mellitus (DM) are to reduce or eliminate diabetic clinical signs while avoiding 24 
hypoglycaemia and other complications.1 Treatment can also result in diabetic remission, which can substantially improve 25 
the quality of life of both cats and their owners.2 Subcutaneous insulin q12h and a low-carbohydrate, high-protein diet 26 
are the mainstays of treatment.3,4 Although several different insulin types have been used for feline DM, a number of 27 
recent guidelines and a systematic review on diabetic remission recommend the use of long-acting insulin preparations 28 
when treating diabetic cats.3–5 Long-acting insulins include protamine zinc insulin (PZI) and the recombinant human 29 
insulin analogues glargine and detemir, and have been associated with a longer duration of action than porcine lente 30 
insulin suspension (PLIS),6 which has an intermediate duration of action. This longer duration of action could help 31 
eliminate diabetic clinical signs, and could also increase a cat’s chance of diabetic remission because early, effective 32 
glycaemic control might reduce the deleterious effects of glucotoxicity on pancreatic beta-cells.5,7,8 However, until 33 
recently, PLIS  (Caninsulin®, MSD Animal Health) had been the only veterinary-licensed insulin in the United Kingdom and 34 
Europe. 35 
 36 
The licensing of a human recombinant protamine zinc insulin solution (PZIR) (ProZinc®, Boehringer Ingelheim) has recently 37 
changed the above situation, and information on transitioning cats from PLIS onto PZIR is therefore necessary. A previous 38 
study examining the efficacy of PZIR in diabetic cats included a small proportion of cats (n=13) that were previously 39 
treated with other insulin types (mainly ultralente and neutral protamine Hagedorn).9 However, no previous studies have 40 
specifically assessed the progress of PLIS-treated cats following transition to PZIR, or evaluated how best to conduct the 41 
transition. The aim of this study was therefore to prospectively evaluate the efficacy of a standardised nadir-based 42 
protocol to transition PLIS-treated cats onto PZIR using the manufacturer-recommended PZIR starting dose, and to 43 
document the effects in individual cats following this transition.  44 
 45 
Materials and Methods 46 
This was a prospective, uncontrolled cohort study conducted at the Royal Veterinary College (RVC) Diabetic Remission 47 
Clinic (DRC) between December 2013 and December 2015. Ethical approval was granted by the RVC Ethics and Welfare 48 
Board, and the Veterinary Medicines Directorate (Animal Test Certificate Number ATC-S-036). To be eligible, cats must 49 
have been diagnosed with DM in the last five months. This reasonably short duration of DM was chosen to increase the 50 
likelihood that some cats might achieve diabetic remission following transitioning because remission is reported to be 51 
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more likely early in the course of a cat’s DM.8 Diagnosis of DM was based on a history of compatible clinical signs (polyuria, 52 
polydipsia, polyphagia) and persistent hyperglycaemia (> 15 mmol/l) at the time of their first trial appointment. These 53 
criteria were similar to those used in a previous study examining the effect of PZIR therapy in diabetic cats.9 Recruited 54 
cats must have been receiving BID PLIS (Caninsulin®, MSD Animal Health) for a minimum of 6 weeks prior to their initial 55 
trial visit. This minimum duration of PLIS treatment aimed to allow cats to achieve stable glycaemic control using PLIS by 56 
the time of their trial recruitment visit. This initial treatment period also allowed cats with concurrent disease or 57 
suspected insulin resistance to be identified prior to their first trial visit. All cats were transitioned onto a high-protein, 58 
low-carbohydrate diet a minimum of 10 days before their first trial appointment. 59 
 60 
Final eligibility was based on the results of underlying disease screening at the initial visit. This involved clinical history 61 
and physical examination by residency-trained or board-certified internal medicine specialists (RG, CS, KH and SN). Cats 62 
then underwent complete blood cell count, serum biochemistry, serum total thyroxine (TT4), serum fructosamine, 63 
insulin-like growth factor-1 (IGF-1) and feline pancreatic lipase immunoreactivity (fPLI) measurement using assays 64 
previously validated for cats. Cystocentesis samples were submitted for urinalysis and bacterial culture, and cats also 65 
received abdominal ultrasonography and echocardiography by a residency-trained specialist.  66 
 67 
Each cat also underwent a 24-hour blood glucose curve (BGC) to assess glycaemic control on their current PLIS regime. 68 
Curves were conducted using the Guardian® REAL-Time Continuous Glucose Monitoring System (CGMS) (Medtronic, 69 
Watford, UK), starting at least 12 hours after all laboratory tests and diagnostic imaging were complete. Curves were 70 
completed using 2-hourly readings with a veterinary handheld glucometer (AlphaTRAK®2, Zoetis) if the CGMS failed 71 
during the 24-hour monitoring period. Each cat’s clinical signs at recruitment were graded using a validated clinical 72 
scoring system (Diabetic Clinical Score) (Table 1).10 The Diabetic Clinical Score (DCS) scores major clinical signs of poor 73 
diabetic control from 0 (absent) to 3 (severe) to generate a final score out of 12. Finally, cat and owner quality of life was 74 
estimated through owners completing the validated DIAQoL-pet quality of life questionnaire for diabetic cats.11 The 75 
DIAQoL-pet generates an Average-Weighted Impact Score (AWIS) to reflect pet and owner quality of life, with more 76 
negative values reflecting a more negative impact of DM. Cats were excluded following the initial visit if they met one or 77 
more of the following exclusion criteria below: Long-acting glucocorticoids administration within the previous 60 days, 78 
or other systemic/inhaled glucocorticoids within the previous 30 days; administration of megesterol acetate or 79 
5 
 
progestogens within the previous 6 months; an IGF-1 concentration of >1000ng/ml, indicating likely 80 
hypersomatotropism12; concurrent hyperthyroidism. Cats that had undergone successful radioactive iodine therapy or 81 
thyroidectomy remained eligible; clinical signs of pancreatitis accompanied by consistent pancreatic changes on 82 
abdominal ultrasonography and/or an fPLI concentration of > 5.4µg/l; concurrent disease of which management would 83 
have affected ability to comply with trial commitments, including International Renal Interest Society stage 3 and 4 84 
chronic kidney disease (CKD); patient aggression or fearfulness. 85 
 86 
Re-examination Protocol 87 
Enrolled cats had their insulin therapy changed to PZIR at the manufacturer’s recommended starting dose of 0.2–0.7 U/kg 88 
q12h at the time of discharge from their first appointment. Doses were chosen based on cats’ previous sensitivity to PLIS. 89 
All doses used throughout the study, including starting doses, were multiples of 0.5 U. Cats were re-examined at the 90 
Diabetic Remission Clinic 2, 4 and 12 weeks after starting PZIR therapy. At each visit, cats underwent assessment of serum 91 
fructosamine, DCS, 24 h water intake and a 24 h BGC. Results of 24 h BGCs at the 0, 2, 4 and 12 week re-examinations 92 
were used to calculate a mean blood glucose (MBG) concentration for each cat at these time points. Owners completed 93 
a repeated DIAQoL-pet questionnaire at 4 and 12 weeks. Cats also received a 12 h BGC at the 1 and 8 week time points, 94 
which could be performed at their primary care clinic, or at home using a handheld glucometer (AlphaTRAK 2; Zoetis), 95 
and could receive additional BGCs at home, or in primary practices, if clinically indicated. 96 
 97 
PZIR dose was altered following each BGC over the 12 week trial using a nadir-based protocol (Table 2). All hypoglycaemic 98 
events, and episodes of diabetic remission, following transition to PZIR were recorded. Diabetic remission was defined as 99 
maintenance of normoglycaemia without receiving antihyperglycaemic medication (with the exception of low-100 
carbohydrate diet) for a minimum of 28 days. This definition was based on the findings of a recent systematic review 101 
examining feline diabetic remission.5 Hypoglycaemia was defined as a blood glucose (BG) concentration of <3 mmol/l 102 
(<54 mg/dl), based on a definition used by recent guidelines on the treatment of feline DM.4 Any clinical signs compatible 103 
with hypoglycaemia, and other potential adverse events, were also recorded. 104 
 105 
A basic comparison of duration of insulin action was carried out between week 0, when cats were treated with PLIS, and 106 
week 4, when treated with PZIR. The week 4 time point was chosen a priori for calculation of PZIR duration of action in 107 
order to provide sufficient time for cats to stabilise on PZIR, yet also being early enough in the trial’s follow-up to avoid 108 
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substantial numbers of trial withdrawals or the development of other complicating factors, such as cats entering diabetic 109 
remission. Duration of insulin action was calculated as the time from insulin administration until the time at which BG 110 
returned to its pre-insulin value following the patient’s BG nadir. This duration of action was calculated for each 12 h 111 
period in a cat’s 24 h BGC, and a mean value was taken. When BG did not return to its pre-insulin value, the duration of 112 
action for that 12 h period was assigned a value of 12 h, which is referred to as ‘long duration of action’ in the remainder 113 
of this study. In contrast, duration of action of <9 h was defined as ‘short duration of action’ on the basis that clinical 114 
signs are often expected when insulin duration is below this cut-off.1 Any BGCs in which insulin was withheld to check for 115 
diabetic remission were excluded from duration of action analysis. 116 
 117 
Statistical Analysis 118 
Continuous and ordinal data were assessed for normality using Shapiro–Wilk normality tests, and examination of 119 
descriptive statistics and histogram plots. Average values are expressed as mean ± SD for normally distributed data, and 120 
as median (interquartile range [IQR]) for non-normally distributed data. 121 
 122 
Linear mixed-effects modelling with compound symmetry covariance structure assessed for change in MBG, serum 123 
fructosamine, q12h insulin dose, DCS and DIAQoL-pet score over the 12 week study period. Twice-daily insulin dose and 124 
DCS were logarithmically transformed in order to meet the model’s assumptions. For parameters that showed significant 125 
change, Fisher’s least significant difference post-hoc comparison was used to assess pairwise differences between each 126 
time point and week 0. 127 
 128 
The proportion of cats affected by short and long duration of insulin action at the week 0 and week 4 time points was 129 
compared using McNemar’s tests. Cats with a short duration of action with either insulin type were evaluated to assess 130 
whether short duration of action was also present using the alternative insulin. A McNemar’s test was also used to assess 131 
the proportion of cats that had at least one hypoglycaemic reading detected during week 0 and week 4 BGCs. 132 
 133 
Results 134 
Thirty-nine cats were examined for trial inclusion between October 2013 and September 2015. Seventeen cats were 135 
excluded with the most common reasons being identification of neoplasia or mass lesions (n=4), likely 136 
hypersomatotropism (n=3), excessive fearfulness or aggression (n=3) and cats being non-insulin dependent based on in-137 
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hospital blood glucose monitoring (n=2). Other reasons for exclusion were hyperthyroidism, gastrointestinal disease, 138 
suspected forebrain disease, hypertrophic cardiomyopathy with congestive heart failure, and owners’ deciding against 139 
study enrolment (all n=1).  140 
 141 
All remaining 22 recruited cats completed the study. They consisted of 12 neutered males and 10 neutered females, and 142 
included 17 domestic shorthaired cats, two domestic longhaired cats and one cat of each of the following breeds: 143 
Abyssinian, Norwegian Forest and Singapura. Mean age was 10.6±2.3 years and mean bodyweight was 4.9±1.4 kg with a 144 
median body condition score of 6 (4–7 out of 9). Cats had been diagnosed with DM a median of 71 (49-93) days prior to 145 
enrolment and had been receiving BID porcine lente insulin for a median of 65 (47–91) days before enrolment. The 146 
median PLIS dose received by cats at time of enrolment was 0.5 U/kg (0.3–0.7 U/kg) BID and median starting dose of PZIR 147 
was 0.5 U/kg (0.3-0.7 U/kg) BID. Seventeen owners (77%) used home blood glucose monitoring (HBGM) as part of their 148 
cat’s diabetic management. 149 
 150 
Table 3 shows change in indicators of diabetic control over the 12 week study, and change in q12h insulin dose over the 151 
trial period is illustrated in Figure 1. A significant change was detected in serum fructosamine (P = 0.00007), q12h insulin 152 
dose (P = 0.02), DIAQol-pet AWIS (P = 0.003) and DCS (P = 8.1 × 10−8) over the study period. Post-hoc analysis revealed 153 
a significant decrease in both serum fructosamine concentration and DCS at every time point compared with week 0, 154 
whereas q12h insulin dose and DIAQoL-pet AWIS had both significantly decreased compared with baseline by week 12 155 
(Table 3). MBG did not significantly change over the study period (P = 0.1). Over the trial period, 12 cats (55.4%) 156 
experienced an increase in body weight, nine cats (41%) experienced a decrease in body weight and body weight 157 
remained stable in one cat. Median water intake while hospitalised decreased from 28.6 ml/kg/day (IQR 19.6–39.0 158 
ml/kg/day) at week 0 to 10.4 ml/kg/day (IQR 7.5–16.8 ml/kg/day) by week 12. Four cats (18.2%) entered diabetic 159 
remission during the study period, and one other cat had stopped PZIR by week 12 and went on to achieve successful 160 
remission. 161 
 162 
The study population underwent a total of 190 12-hour periods of blood glucose monitoring during the trial and 163 
hypoglycaemia was detected during 30 (15.8%) 12-hour BGCs. Five cats experienced a hypoglycaemic episode associated 164 
with clinical signs. One clinical hypoglycaemic episode was detected during a BGC, whereas four were confirmed by 165 
owners performing a BG check on their cat at home. Clinical signs included subdued demeanour (n=1), incoordination 166 
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(n=3), incoordination and blindness (n=1) and collapse (n=1). Three cases resolved with feeding and two cases recovered 167 
following intravenous glucose treatment. One of the five cats with symptomatic hypoglycaemia subsequently achieved 168 
remission. Seven out of 22 cats (31.8%) became hypoglycaemic during their week 0 BGC using PLIS, whereas four out of 169 
19 cats (21.1%) that had a BGC at week 4 using PZIR experienced hypoglycaemia during their week 4 curve (p=1.0). One 170 
cat developed a transient subcutaneous swelling at the site of PZIR administration. This swelling resolved without 171 
treatment. 172 
 173 
Three cats were excluded from the analysis of duration of insulin action due to cessation of insulin by the 4-week time 174 
point (n=2) or missing the 4-week re-examination due to owner illness (n=1). Six cats showed a short duration of action 175 
on PLIS compared to 2 cats after 4 weeks on PZIR (p=0.18) (Figure 2). Six cats had long duration of action when treated 176 
with PZIR, compared to 3 cats when treated with PLIS (p=0.5). All six cats that had a short duration of insulin action on 177 
PLIS, had a duration of PZIR action of ≥9 hours 4 weeks after transitioning. Both cats with short duration of action on PZIR 178 
had a duration of action ≥9 hours on PLIS (Figure 2).  179 
 180 
Discussion 181 
This study examined the efficacy of transitioning BID PLIS-treated diabetic cats onto BID PZIR using a standardised nadir-182 
led insulin dosing protocol. Transitioning was associated with an improvement in both fructosamine concentration and 183 
DM-related clinical signs within two weeks of starting PZIR. Pet and owner quality of life, measured by the DIAQoL-pet 184 
tool, had significantly improved within 12 weeks of starting PZIR treatment, and 22.7% of cats achieved diabetic remission 185 
after starting PZIR. Individual cats that suffered from short duration of action on PLIS, showed a resolution of this problem 186 
4 weeks’ following transition onto PZIR. Hypoglycaemia was the most common side effect, as expected, although was 187 
rarely symptomatic, and was treated successfully. Hypoglycaemia was not more common with either insulin type when 188 
two, a priori, set time points were compared (t=0 and t=4 weeks post-transition).  189 
 190 
The findings of this study support that PZIR is an effective therapy for feline DM, and that PZIR treatment can be 191 
associated with a rapid improvement in fructosamine concentration and clinical signs of DM in cats previously treated 192 
with PLIS, when used in a nadir-based protocol alongside a low-carbohydrate, high-protein diet. These findings agree 193 
with two previous trials which examined the efficacy of PZIR,9 or related bovine- and porcine-derived PZI,13 in both insulin-194 
naïve and previously-treated diabetic cats. These studies found that approximately 85% of the whole study population 195 
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achieved good glycaemic control within 45 days of starting PZI therapy, and 65–70% of previously-treated feline diabetics 196 
showed good diabetic control after 45 days of PZI therapy. However, both of these studies contained only one cat treated 197 
with PLIS q12h, so were unable to assess specifically the outcome of transitioning PLIS-treated cats onto PZI. This new 198 
information will be of particular interest to veterinarians looking for alternative insulin types for feline diabetics in the 199 
UK and Europe where PLIS has, until recently, been the only licensed veterinary insulin. 200 
 201 
The current study is the first to include quality-of-life measurement as a treatment outcome and found that cat and 202 
owner quality of life, measured using a validated quality-of-life tool, was unchanged from baseline after 1 month of PZIR 203 
treatment, and had significantly improved by the end of the 12 week study. This improvement could be owing to owners 204 
and cats becoming accustomed to the treatment of DM, and that some cats had achieved diabetic remission by this time 205 
point. Remission would be expected to substantially increase the wellbeing of cats and their owners. Change in patients’ 206 
clinical signs of DM has been assessed by previous studies on PZI treatment in diabetic cats.9,13 However, this is also the 207 
first study to use a validated clinical scoring system10 as a treatment outcome. This aimed to more consistently assess 208 
changes in clinical signs in a standardised fashion, representing an improvement on the methodology of previous trials. 209 
 210 
PZI is proposed to offer better glycaemic control than PLIS in diabetic cats.3,4 This recommendation is founded on previous 211 
studies, which have shown PZI to have a longer duration of action compared to lente insulin in healthy cats,5 as well as 212 
compared to other intermediate-duration insulin types in diabetic cats.14 To our knowledge, no previous study has 213 
compared the duration of action of PZIR and PLIS in diabetic cats. Assessing duration of insulin action can be particularly 214 
challenging in diabetic cats because duration of action cannot be reliably estimated when cats have poorly-controlled 215 
DM.1 Also, diabetic cats typically receive insulin therapy every 12 hours so measuring insulin duration of >12 hours would 216 
not be possible without disrupting their usual treatment regime.  This limitation prevented a precise comparison of insulin 217 
duration in the current study, which instead assessed duration of action characteristics by focussing on those cats that 218 
had a short duration of action when treated with either insulin type. All cats with a short duration of insulin action on 219 
PLIS showed a resolution of this problem when treated with PZIR. However, two cats were found to have a short duration 220 
of action when transitioned to PZIR, but did not experience this problem on PLIS. Furthermore, nine other cats showed a 221 
decreased duration of action with PZIR compared with PLIS, but remained above the limit for short duration of action 222 
(Figure 2). These findings support previous observations that individual diabetic cats can be unpredictable in their 223 
response to different insulin types,1 or their response can be difficult to reliably ascertain due to documented day-to-day 224 
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variability of BGCs in feline diabetics.15 The employed CGMS had a maximum measureable blood glucose limit of >22.2 225 
mmol/l (400 mg/dl) and this could have artificially reduced the estimated duration of action in some cats.  226 
 227 
The only adverse events recorded in this study were hypoglycaemia, as expected, and one episode of transient swelling 228 
at the site of PZIR administration. The latter has been previously reported in PZIR- treated cats.9 Hypoglycaemia was 229 
detected in 15.8% of all 12-hour BGCs in the current study. This is slightly greater than the proportion of 9.0% detected 230 
in a trial examining the use of bovine/porcine PZI,13 but less than the proportion of 22.2% reported in a previous study 231 
examining PZIR.9 A higher proportion of cats in the current study experienced confirmed clinical hypoglycaemia compared 232 
to these two previous trials. However, most cat owners in the current study used HBGM to monitor their cat’s DM, 233 
whereas neither previous trial utilised HBGM. Four out of five clinical hypoglycaemic episodes in the current study were 234 
diagnosed by owners performing a one-off BG measurement at home. This frequent use of HBGM likely increased the 235 
number of confirmed clinical hypoglycaemic episodes compared to previous trials because owners were likely to 236 
promptly check their cat’s blood glucose if concerned about their pet’s demeanour. This is in contrast to a previous PZIR 237 
study where BG measurement could not be performed at several times of suspected hypoglycaemia.9 Finally, the current 238 
study predominantly carried out BGCs using CGMSs, which have been shown to detect hypoglycaemic BGC nadirs that 239 
might be missed during curves using handheld glucometers.16 This is likely to have ensured that most hypoglycaemic 240 
episodes in this trial were successfully documented, especially when combined with the frequent use of HBGM. The 241 
current study is therefore likely to provide an accurate estimate of the incidence of hypoglycaemia among diabetic cats 242 
transitioned to PZIR.  243 
 244 
This study did not document an improvement in MBG concentration over the duration of the study, despite an 245 
improvement in serum fructosamine concentration, diabetic clinical score and several cats entering diabetic remission. 246 
As mentioned, the CGMS used to perform BGCs in this study had a maximum measureable blood glucose concentration 247 
of 22.2mmol/l (400mg/dl) and this might have lowered the MBG values in some cats. Also, the BGCs, from which MBG 248 
was calculated, were all performed in hospital and so stress-related hyperglycaemia from hospitalisation might have 249 
affected blood glucose measurements.17 The study did aim to minimise stress-related hyperglycaemia by using a CGMS 250 
to perform BGCs and ensuring that all BGCs were performed more than 12 hours after hospital admission. Although no 251 
significant change was detected in MBG, the fact that serum fructosamine concentration improved over the study period 252 
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suggests that these in-hospital curves might not reflect cat’s diabetic control between re-examination visits. The earlier 253 
mentioned day-to-day variability of blood glucose curves, is also likely associated with this apparent discrepancy.16  254 
 255 
This study has some limitations. Although several markers of glycaemic control improved in included cats following their 256 
transition from PLIS to PZIR, the current trial was not designed to demonstrate unequivocally that one insulin preparation 257 
is superior to the other. For instance, it is theoretically possible that included cats would also have experienced an 258 
improvement in their diabetic control had they remained on PLIS therapy for longer. Despite this, cats in the current 259 
study showed a rapid, significant improvement in diabetic clinical signs after starting PZIR, whereas a previous trial found 260 
that three months of PLIS therapy was needed to produce a significant improvement in clinical signs when starting 261 
diabetic cats on PLIS.18 262 
 263 
Other factors might also have played a role in the documented improvement post-transition in the current trial. These 264 
factors include the use of a nadir-based protocol, support from a dedicated DM clinic during the trial, and the fact that 265 
cats were transitioned onto a low-carbohydrate diet as part of the study protocol. Dietary carbohydrate restriction is 266 
likely to promote good glycaemic control in diabetic cats.19 In this study, cats’ transition to a low-carbohydrate, high-267 
protein diet was carried out before trial recruitment to allow the benefits of feeding a low-carbohydrate, high-protein 268 
diet to take effect before their first study visit. Although the minimum time for this diet change was 10 days prior to 269 
enrolment, recruited cats were fed a low-carbohydrate high-protein diet for a median of 29 days before their first trial 270 
appointment. A previous study found that insulin-treated diabetic cats experienced a significant decrease in MBG within 271 
4 weeks of transitioning to a low-carbohydrate diet.19 It is therefore likely that the benefits of changing to a low-272 
carbohydrate, high-protein diet in the current study were already apparent by many cats’ first trial appointment and that 273 
subsequent improvements in glycaemic control were more related to other factors, including the change from PLIS to 274 
PZIR. Overall, an unbiased direct comparison of PZIR and PLIS would ultimately require an adequately powered, well 275 
designed, randomised clinical trial, which is currently lacking in the veterinary literature, as discussed in a recent 276 
systematic review of feline diabetes treatment.5 However, the transition process described in this study provides valuable 277 
information, which can now be used to inform effective and safe transition protocols for cats requiring transition from 278 
PLIS to PZIR, for one reason or another. 279 
  280 
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Conclusions 281 
Diabetic cats treated with intermediate-acting PLIS can be transitioned successfully onto long-acting PZIR using a nadir-282 
led protocol and the manufacturer-recommended starting dose. Overall, transitioning to PZIR was associated with an 283 
improvement in fructosamine, diabetic clinical signs, and pet and owner quality of life, and a proportion of cats entered 284 
diabetic remission after starting PZIR therapy. Incidence of hypoglycaemia was similar to previously described with PZI 285 
use in cats. This documented incidence of hypoglycaemia, the potential for diabetic remission, and the efficacy of PZIR at 286 
modest dosages could nevertheless mean that conservative PZIR dosing should be used in cats where close monitoring 287 
cannot be performed. In conclusion, this study provides a framework for transitioning diabetic cats from PLIS to PZIR, if 288 
needed. Additionally, veterinary-licensed human recombinant PZI proved to be an effective treatment for feline DM and 289 
was associated with increased duration of action in those PLIS-treated cats with short duration of action. Licensed long-290 
acting PZIR therefore provides a viable alternative treatment option to licensed intermediate-acting PLIS in feline 291 
diabetics, especially since recent recommendation emphasise the preferential use of long-acting insulin types. 292 
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Table 1: Diabetic Clinical Score (DCS) used to grade the severity of diabetes-associated clinical signs in 362 
participating cats  363 
Clinical Sign Being Scored 
Severity (compared to prior to onset of 
diabetes mellitus) 
Assigned 
Score 
Unintended weight loss over the past 2 
months 
(Assessed using bodyweight records or  
measurements) 
None, intended weight loss or weight gain 
Mild (<5% loss) 
Moderate (5-10% loss) 
Severe (>10% loss) 
0 
1 
2 
3 
Increased drinking and/or urination 
(Assessed by questioning owner) 
None 
Mild – some increase noted 
Moderate – increased filling of water bowl 
Severe – constantly seen to drink 
0 
1 
2 
3 
Increased appetite 
(Assessed by questioning owner) 
Normal or decreased appetite 
Mild – finishes food eagerly 
Moderate – finishes food eagerly and begs for 
more 
Severe – obsessed with food 
0 
1 
2 
3 
Decreased activity/ attitude 
(Assessed by questioning owner) 
Normal or increased activity 
Mild – slightly less active 
Moderate – certainly less active 
Severe – mainly lying around 
0 
1 
2 
3 
 
Total score /12 
364 
16 
 
Table 2: Nadir-based protocol used to alter PZIR dose according to the results of blood glucose curves 365 
during the 12-week study period 366 
Blood Glucose Curve Results Action Taken 
Pre-insulin BG < 10mmol/l Withhold insulin for 12 hours to check for remission 
Pre-insulin BG > 10mmol/l 
+ nadir of < 3mmol/l 
+ nadir 3 - 6 mmol/l 
+ nadir > 6 mmol/l 
 
Reduce dose by 0.5-1 U/injection 
Keep dose unchanged 
Increase dose by 0.5-1 U/injection 
Hypoglycaemia associated with clinical signs Reduce total dose by 50% 
Abbreviations: BG, Blood Glucose.367 
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Table 3: Change in indicators of diabetic control among recruited cats over the 12-week study period. 368 
The table also indicates whether these changes reached statistical significance in linear mixed effects 369 
modelling. 370 
Study 
Timepoint 
(week) 
BID Insulin Dose 
(U/kg) 
Mean BG 
(mmol/l) 
(mg/dl) 
Serum fructosamine 
(µmol/l) 
Diabetic 
Clinical Score  
(out of 12) 
DIAQoL-pet AWIS 
0 0.48 (0.32 – 0.75) 
13.2 (9.1 – 18.8) 
237.6 (163.8 – 338.4) 
469 (358 – 588) 3 (1 – 6) -1.7 (-3.4 - -1.0) 
2 0.52 (0.30 – 0.65) 
11.2 (6.2 – 16.1) 
201.6 (111.6 – 289.8) 
428 (349 – 505) * 3 (0 – 4) * - 
4 0.46 (0.19 – 0.67) 
11.5 (7.2 – 16.3) 
207.0 (129.6 – 293.4) 
401 (309 – 454) ** 0 (0 – 2) *** -1.8 (-2.8 - -0.8) 
12 0.39 (0.18 – 0.61) ** 
10.8 (8.3 – 15.4) 
194.4 (149.4 – 277.2) 
338 (266 – 486) *** 0 (0 – 2) *** -1.0 (-2.2 - -0.4) ** 
Abbreviations: BID, Twice daily; BG, Blood glucose; AWIS, Average weighted impact score. All average 371 
values are reported as median (interquartile range). *, ** and *** indicate a significant difference 372 
compared to week 0 value in post-hoc analysis (* indicates p<0.5, ** indicates p<0.01, *** indicates 373 
p<0.001) 374 
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Figure 1. Scatterplot showing change in twice-daily insulin dose over study period. Red symbols indicate 375 
values when treated with porcine lente insulin suspension q12h, and blue symbols indicate values when 376 
treated with protamine zinc insulin solution q12h. **Significant difference compared with week 0 (P 377 
<0.01). Vertical line and error bars indicate median and interquartile range. 378 
 379 
 380 
  381 
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Figure 2: Paired scatterplot showing duration of action of porcine lente insulin suspension (PLIS) q12h and 382 
protamine zinc insulin solution (PZIR) q12h in individual cats. Dashed line indicates short duration of 383 
insulin action (<9 h). Red symbols indicate duration when treated with PLIS q12h, and blue symbols 384 
indicate duration when treated with PZIR q12h. Pairs of values from individual cats have joining lines. Two 385 
pairs of cats had the same duration of action before and after transitioning (two decreasing from 12 h to 386 
10.9 h and two increasing from 7 h to 12 h), resulting in only 17 data pairs being visible on the graph. 387 
 388 
